Document is current
Any future updates will be listed below
-
Authors
Pena, Izabella A. https://orcid.org/0000-0001-5242-3724
Shi, Jeffrey S. https://orcid.org/0000-0001-7938-1405
Chang, Sarah M.
Yang, Jason
Block, Samuel
Adelmann, Charles H.
Keys, Heather R. https://orcid.org/0000-0003-1371-2288
Ge, Preston
Bathla, Shveta
Witham, Isabella H. https://orcid.org/0000-0003-3288-2944
Sienski, Grzegorz
Nairn, Angus C. https://orcid.org/0000-0002-7075-0195
Sabatini, David M.
Lewis, Caroline A. https://orcid.org/0000-0003-1787-5084
Kory, Nora https://orcid.org/0000-0001-5307-9021
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
Heiman, Myriam https://orcid.org/0000-0002-6365-8673
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 8 January 2025
First Online: 24 January 2025
Competing interests
: M.G.V.H. discloses that he is an advisor for Agios Pharmaceuticals, iTeos Therapeutics, Sage Therapeutics, Pretzel Therapeutics, Droia Ventures, MPM Capital, and Auron Therapeutics. G.S. is currently an employee and shareholder of AstraZeneca. All other authors declare that they have no competing interests.
